Drug Profile
Sugemalimab - CStone Pharmaceuticals/EQRx
Alternative Names: Cejemly; CS-1001; Sugelimab; WBP-3155; Zegema; Zegemet; Zegemex; ZEJIEMEILatest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator CStone Pharmaceuticals
- Developer Bayer; CStone Pharmaceuticals; EQRx
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer; Oesophageal cancer
- Registered Gastric cancer
- Preregistration Extranodal NK-T-cell lymphoma
- Phase III T-cell lymphoma
- Phase II Hodgkin's disease
- Phase I/II Liver cancer; Solid tumours
- No development reported Small cell lung cancer
Most Recent Events
- 15 Mar 2024 Registered for Gastric cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Second-line therapy or greater) in China (IV)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV, Infusion)